{"id":157,"date":"2020-10-02T11:56:09","date_gmt":"2020-10-02T10:56:09","guid":{"rendered":"http:\/?page_id=157"},"modified":"2024-06-27T08:56:53","modified_gmt":"2024-06-27T07:56:53","slug":"jean-philippe-guilloux","status":"publish","type":"page","link":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/?page_id=157","title":{"rendered":"Jean-Philippe Guilloux"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized is-style-rounded\"><a href=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange.jpg\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange.jpg\" alt=\"\" class=\"wp-image-563\" style=\"width:200px;height:200px\" width=\"200\" height=\"200\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange.jpg 850w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange-300x300.jpg 300w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange-150x150.jpg 150w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2023\/10\/cropped-Lunettes_Orange-768x768.jpg 768w\" sizes=\"(max-width: 200px) 100vw, 200px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Assistant Professor<\/h2>\n\n\n\n<p>PhD, HDR<\/p>\n\n\n\n<p>Tel: &nbsp;+33(0)1.80.00.63.35<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-mail  wp-block-social-link\"><a href=\"mailto:&#106;e&#097;&#110;-ph&#105;&#108;&#105;ppe&#046;&#103;u&#105;lloux&#064;uni&#118;e&#114;si&#116;&#101;&#045;pa&#114;&#105;&#115;&#045;s&#097;cl&#097;&#121;&#046;&#102;r\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19,5H5c-1.1,0-2,.9-2,2v10c0,1.1.9,2,2,2h14c1.1,0,2-.9,2-2V7c0-1.1-.9-2-2-2zm.5,12c0,.3-.2.5-.5.5H5c-.3,0-.5-.2-.5-.5V9.8l7.5,5.6,7.5-5.6V17zm0-9.1L12,13.6,4.5,7.9V7c0-.3.2-.5.5-.5h14c.3,0,.5.2.5.5v.9z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Mail<\/span><\/a><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/orcid.org\/0000-0003-0982-3751\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/orcid-1.png\" alt=\"\" class=\"wp-image-594\" style=\"object-fit:cover;width:30px;height:30px\" width=\"30\" height=\"30\"\/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/scholar.google.com\/citations?hl=fr&amp;user=_M4JUnsAAAAJ&amp;view_op=list_works&amp;sortby=pubdate\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-1024x1024.png\" alt=\"\" class=\"wp-image-583\" style=\"object-fit:cover;width:30px;height:30px\" width=\"30\" height=\"30\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-1024x1024.png 1024w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-300x300.png 300w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-150x150.png 150w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-768x768.png 768w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-1536x1536.png 1536w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon-1080x1080.png 1080w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/google-scholar-icon.png 2048w\" sizes=\"(max-width: 30px) 100vw, 30px\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.researchgate.net\/profile\/Jean-Philippe-Guilloux\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/RG.svg_.png\" alt=\"\" class=\"wp-image-589\" style=\"object-fit:cover;width:30px;height:30px\" width=\"30\" height=\"30\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/RG.svg_.png 1024w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/RG.svg_-300x300.png 300w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/RG.svg_-150x150.png 150w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/RG.svg_-768x768.png 768w\" sizes=\"(max-width: 30px) 100vw, 30px\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.webofscience.com\/wos\/author\/record\/B-3726-2015\"><img decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/Researcherid_logo.png\" alt=\"\" class=\"wp-image-601\" style=\"height:30px\" height=\"30\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/Researcherid_logo.png 328w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/Researcherid_logo-300x69.png 300w\" sizes=\"(max-width: 328px) 100vw, 328px\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/myncbi\/jean-philippe.guilloux.1\/bibliography\/public\"><img decoding=\"async\" src=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/US-NLM-PubMed-Logo.svg_-1024x364.png\" alt=\"\" class=\"wp-image-591\" style=\"height:30px\" height=\"30\" srcset=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/US-NLM-PubMed-Logo.svg_-1024x364.png 1024w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/US-NLM-PubMed-Logo.svg_-300x107.png 300w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/US-NLM-PubMed-Logo.svg_-768x273.png 768w, http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/wp-content\/uploads\/2024\/06\/US-NLM-PubMed-Logo.svg_.png 1440w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-twitter  wp-block-social-link\"><a href=\"https:\/\/twitter.com\/jpguilloux\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Twitter<\/span><\/a><\/li><\/ul>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Area of Research<\/h3>\n\n\n\n<p>Neuropharmacology, Neurobiology of Depression\/Anxiety, Animal Models of Psychiatric Disorders, Genetics.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Expertise<\/h3>\n\n\n\n<p>Expression profiles of genes in limbic areas in animal models of depression: links with human pathology? Gene Networks involved in mood disorders.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Research Theme<\/h3>\n\n\n\n<p>I graduated in 2003 and obtained fundings to do pursue with a PhD in neuropharmacology where I studied the mechanism of action of pindolol in its potentiation of effects of antidepressant treatment (Universit\u00e9 Paris Sud, France). I obtained my Ph.D. in Neuropharmacology in May 2006 and was awarded for his thesis the same year. From 2006 to 2008, I studied the beneficial effects of nicotine on motor impairment in the 6-OHDA rat model of Parkinson during a first postdoctoral position (Inserm, Paris, France). From 2008 to 2011, I joined Etienne Sibille Lab (University of Pittsburgh, USA), and studied the effects of major depressive disorders on gene expression in the amygdala of depressed subjects and in animal models of the pathology. Since 2011, I am an associate professor, working on the molecular causes of antidepressant treatment resistance in relevant animal models, with the goal of finding peripheral and central biomarkers of response to antidepressant therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Selected Publications<\/h3>\n\n\n\n<p>Nguyen, T. M. L., J.-P. Guilloux, C. Defaix, I. Mendez-David, I. Etting, J.-C. Alvarez, J. C. McGowan, J. N. Highland, P. Zanos, J. Lovett, R. Moaddel, E. Corruble, D. J. David, T. D. Gould, C. A. Denny and A. M. Gardier (2024).\u00a0\u00bbKetamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.\u00a0\u00bb bioRxiv.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Martin, H., A. Coursan, J. Lallement, M. Di Miceli, J. Kandiah, I. Raho, J. Buttler, J. P. Guilloux, P. De Deurwaerdere, S. Laye, H. R. Vanessa, B. P. Guiard, C. Magnan, C. Cruciani-Guglielmacci and X. Fioramonti (2023). \u00ab\u00a0Serotonergic neurons are involved in the counter-regulatory response to hypoglycemia.\u00a0\u00bb J Neuroendocrinol: e13344.<br><\/p>\n\n\n\n<p>Guilloux, J. P., T. M. L. Nguyen and A. M. Gardier (2023). \u00ab\u00a0[Ketamine: a neuropsychotropic drug with an innovative mechanism of action].\u00a0\u00bb Biol Aujourdhui 217(3-4): 133-144.<br><\/p>\n\n\n\n<p>Doan, J., C. Defaix, I. Mendez-David, A. M. Gardier, R. Colle, E. Corruble, J. C. McGowan, D. J. David, J. P. Guilloux and L. Tritschler (2023). \u00ab\u00a0Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.\u00a0\u00bb Fundam Clin Pharmacol.<br><\/p>\n\n\n\n<p>Mendez-David, I., R. Schofield, L. Tritschler, R. Colle, J. P. Guilloux, A. M. Gardier, E. Corruble, R. Hen and D. J. David (2022). \u00ab\u00a0Reviving through human hippocampal newborn neurons.\u00a0\u00bb Encephale 48(2): 179-187.<\/p>\n\n\n\n<p>Lebeau, R. H., I. Mendez-David, L. Kucynski-Noyau, C. Henry, D. Attali, M. Plaze, R. Colle, E. Corruble, A. M. Gardier, R. Gaillard, J. P. Guilloux and D. J. David (2022). \u00ab Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine. \u00bb Front Pharmacol 13: 993449.&nbsp;<\/p>\n\n\n\n<p>Felice, D., J. P. Guilloux, A. Pehrson, Y. Li, I. Mendez-David, A. M. Gardier, C. Sanchez and D. J. David (2018). \u00ab\u00a0Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism.\u00a0\u00bb Front Pharmacol 9: 204.<\/p>\n\n\n\n<p>&nbsp;Tritschler, L., M. A. Kheirbek, Y. L. Dantec, I. Mendez-David, J. P. Guilloux, C. Faye, J. Doan, T. H. Pham, R. Hen, D. J. David and A. M. Gardier (2017). \u00ab\u00a0Optogenetic activation of granule cells in the dorsal dentate gyrus enhances dopaminergic neurotransmission in the Nucleus Accumbens.\u00a0\u00bb Neurosci Res.<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., C. Boursier, V. Domergue, R. Colle, B. Falissard, E. Corruble, A. M. Gardier, J. P. Guilloux and D. J. David (2017). \u00ab\u00a0Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety\/Depression.\u00a0\u00bb Front Cell Neurosci 11: 237.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Mendez-David, I., J. P. Guilloux, M. Papp, L. Tritschler, E. Mocaer, A. M. Gardier, S. Bretin and D. J. David (2017). \u00ab\u00a0S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms.\u00a0\u00bb Front Pharmacol 8: 462.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., A. M. Gardier and D. J. David (2017). \u00ab\u00a0New targets and modalities of antidepressant drugs development.\u00a0\u00bb La lettre du Pharmacologue 31(1): 12-18.<\/p>\n\n\n\n<p>&nbsp;Mekiri, M., A. M. Gardier, D. J. David and J. P. Guilloux (2017). \u00ab\u00a0Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice.\u00a0\u00bb Exp Clin Psychopharmacol 25(2): 94-104.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., B. A. Samuels, I. Mendez-David, A. Hu, M. Levinstein, C. Faye, M. Mekiri, E. Mocaer, A. M. Gardier, R. Hen, A. Sors and D. J. David (2017). \u00ab\u00a0S 38093, a histamine H3 antagonist\/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice.\u00a0\u00bb Sci Rep 7: 42946.<\/p>\n\n\n\n<p>&nbsp;Besson, M., S. Guiducci, S. Granon, J. P. Guilloux, B. Guiard, C. Reperant, P. Faure, S. Pons, G. Cannazza, M. Zoli, A. M. Gardier and U. Maskos (2016). \u00ab\u00a0Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments.\u00a0\u00bb Psychopharmacology (Berl) 233(18): 3297-3314.<\/p>\n\n\n\n<p>&nbsp;Darcet, F., A. M. Gardier, R. Gaillard, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.\u00a0\u00bb Pharmaceuticals (Basel) 9(1).<\/p>\n\n\n\n<p>&nbsp;David D. J., L. Tritschler, J. P. Guilloux, A. M. Gardier, C. Sanchez, R. Gaillard (2016). \u00ab\u00a0Pharmacological properties of vortioxetine and its pre-clinical consequences.\u00a0\u00bb Enc\u00e9phale. 42: 1S12<\/p>\n\n\n\n<p>&nbsp;Costemale-Lacoste, J. F., J. P. Guilloux and R. Gaillard (2016). \u00ab\u00a0The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: a review of the literature.\u00a0\u00bb Encephale In Press.<\/p>\n\n\n\n<p>&nbsp;Darcet, F., A. M. Gardier, D. J. David and J. P. Guilloux (2016). \u00ab\u00a0Chronic 5-HT receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Neurosci Lett 616: 197-203.<\/p>\n\n\n\n<p>&nbsp;Siopi, E., M. Denizet, M. M. Gabellec, F. de Chaumont, J. C. Olivo-Marin, J. P. Guilloux, P. M. Lledo and F. Lazarini (2016). \u00ab\u00a0Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice.\u00a0\u00bb J Neurosci 36(2): 518-531.<\/p>\n\n\n\n<p>&nbsp;Quesseveur, G., A. C. Petit, H. T. Nguyen, L. Dahan, R. Colle, S. Rotenberg, I. Seif, P. Robert, D. David, J. P. Guilloux, A. M. Gardier, C. Verstuyft, L. Becquemont, E. Corruble and B. P. Guiard (2016). \u00ab\u00a0Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.\u00a0\u00bb Neuropharmacology 105: 142-153.<\/p>\n\n\n\n<p>&nbsp;Colle, R., F. Gressier, C. Verstuyft, E. Deflesselle, J. P. Lepine, F. Ferreri, P. Hardy, J. P. Guilloux, A. C. Petit, B. Feve, B. Falissard, L. Becquemont and E. Corruble (2015). \u00ab\u00a0Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients.\u00a0\u00bb J Affect Disord 175C: 233-240.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., S. Bassi, Y. Ding, C. Walsh, G. Turecki, G. Tseng, J. M. Cyranowski and E. Sibille (2015). \u00ab\u00a0Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.\u00a0\u00bb Neuropsychopharmacology 40(3): 701-710.<\/p>\n\n\n\n<p>&nbsp;Ding, Y., L.-C. Chang, W. Wang, J.-P. Guilloux, J. Parrish, H. Oh, B. J. French, D. A. Lewis, G. C. Tseng and E. Sibille (2015). \u00ab\u00a0Molecular and Genetic Characterization of Depression: Overlap with Other Psychiatric Disorders and Aging.\u00a0\u00bb Molecular Neuropsychiatry 1(1): 1-12.<\/p>\n\n\n\n<p>&nbsp;Tritschler, L., D. Felice, R. Colle, J. P. Guilloux, E. Corruble, A. M. Gardier and D. J. David (2014). \u00ab\u00a0Vortioxetine for the treatment of major depressive disorder.\u00a0\u00bb Expert Rev Clin Pharmacol: 1-15.<\/p>\n\n\n\n<p>&nbsp;Darcet, F., I. Mendez-David, L. Tritschler, A. M. Gardier, J. P. Guilloux and D. J. David (2014). \u00ab\u00a0Learning and memory impairments in a neuroendocrine mouse model of anxiety\/depression.\u00a0\u00bb Front Behav Neurosci 8: 136.<\/p>\n\n\n\n<p>&nbsp;Le Dantec, Y., G. Hache, J. P. Guilloux, B. P. Guiard, D. J. David, J. Adrien and P. Escourrou (2014). \u00ab\u00a0NREM sleep hypersomnia and reduced sleep\/wake continuity in a neuroendocrine mouse model of anxiety\/depression based on chronic corticosterone administration.\u00a0\u00bb Neuroscience 274: 357-368..<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., I. Mendez-David, A. Pehrson, B. P. Guiard, C. Reperant, S. Orvoen, A. M. Gardier, R. Hen, B. Ebert, S. Miller, C. Sanchez and D. J. David (2013). \u00ab\u00a0Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.\u00a0\u00bb Neuropharmacology 73: 147-159.<\/p>\n\n\n\n<p>&nbsp;Douillard-Guilloux, G., J. P. Guilloux, D. A. Lewis and E. Sibille (2013). \u00ab\u00a0Anticipated brain molecular aging in major depression.\u00a0\u00bb Am J Geriatr Psychiatry 21(5): 450-460.<\/p>\n\n\n\n<p>&nbsp;Xia, L., C. Delomenie, I. David, Q. Rainer, M. Marouard, H. Delacroix, D. J. David, A. M. Gardier and J. P. Guilloux (2012). \u00ab\u00a0Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice.\u00a0\u00bb Neuroscience letters 521(1): 20-25.<\/p>\n\n\n\n<p>&nbsp;Besson, M., V. David, M. Baudonnat, P. Cazala, J. P. Guilloux, C. Reperant, I. Cloez-Tayarani, J. P. Changeux, A. M. Gardier and S. Granon (2012). \u00ab\u00a0Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice.\u00a0\u00bb Psychopharmacology 220(1): 1-14.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., G. Douillard-Guilloux, R. Kota, X. Wang, A. M. Gardier, K. Martinowich, G. C. Tseng, D. A. Lewis and E. Sibille (2012). \u00ab\u00a0Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.\u00a0\u00bb Molecular psychiatry 17(11): 1130-1142.<\/p>\n\n\n\n<p>&nbsp;Tripp, A., H. Oh, J. P. Guilloux, K. Martinowich, D. A. Lewis and E. Sibille (2012). \u00ab\u00a0Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder.\u00a0\u00bb The American journal of psychiatry 169(11): 1194-1202.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., D. J. David, L. Xia, H. T. Nguyen, Q. Rainer, B. P. Guiard, C. Reperant, T. Deltheil, M. Toth, R. Hen and A. M. Gardier (2011). \u00ab\u00a0Characterization of 5-HT(1A\/1B)-\/- mice: an animal model sensitive to anxiolytic treatments.\u00a0\u00bb Neuropharmacology 61(3): 478-488.<\/p>\n\n\n\n<p>&nbsp;Rainer, Q., L. Xia, J. P. Guilloux, C. Gabriel, E. Mocaer, R. Hen, E. Enhamre, A. M. Gardier and D. J. David (2011). \u00ab\u00a0Beneficial behavioural and neurogenic effects of agomelatine in a model of depression\/anxiety.\u00a0\u00bb Int J Neuropsychopharmacol: 1-15.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., M. Seney, N. Edgar and E. Sibille (2011). \u00ab\u00a0Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex.\u00a0\u00bb J Neurosci Methods 197(1): 21-31.<\/p>\n\n\n\n<p>&nbsp;Guilloux JP, Gaiteri C, Sibille E. (2010). \u00abNetwork analysis of positional candidate genes of schizophrenia highlights\u2026more than\u2026 myelin-related pathways. Mol Psychiatry\u00bb. Aug;15(8):786-8.&nbsp;<\/p>\n\n\n\n<p>&nbsp;Gaiteri C, Guilloux JP, Lewis DA, Sibille E. (2010) \u00abAltered Gene Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major Depression\u00bb. PLoS One. Apr 1;5(4):e9970<\/p>\n\n\n\n<p>&nbsp;Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, Pr\u00e9mont J. (2010). Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One. Mar 19;5(3):e9777.<\/p>\n\n\n\n<p>&nbsp;Massart, R., J. P. Guilloux, V. Mignon, P. Sokoloff and J. Diaz (2009). \u00ab\u00a0Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents.\u00a0\u00bb Eur J Neurosci 30(3): 397-414.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., D. J. David, B. P. Guiard, F. Chenu, C. Reperant, M. Toth, M. Bourin and A. M. Gardier (2006). \u00ab\u00a0Blockade of 5-HT1A receptors by (+\/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice.\u00a0\u00bb Neuropsychopharmacology 31(10): 2162-2172.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">&nbsp;&nbsp; Book Chapters<\/h4>\n\n\n\n<p>&nbsp;Mendez-David, I., D. J. David, J.-P. Guilloux, R. Hen and A. M. Gardier (2015). \u00ab\u00a05-HT4 Receptor Subtype, \u03b2-Arrestin Level, and Rapid-Onset Effects of Antidepressant Drugs.\u00a0\u00bb&nbsp; 95: 101-121.<\/p>\n\n\n\n<p>&nbsp;David, D. J., B. P. Guiard, J. P. Guilloux and A. M. Gardier (2013). Pharmacologie des antid\u00e9presseurs : mod\u00e8les animaux. Les Antid\u00e9presseurs. E. Corruble. Paris, Flammarion M\u00e9decine\/Sciences: 40-51.<\/p>\n\n\n\n<p>&nbsp;Guilloux, J. P., D. J. David, B. A. Samuels, I. David, A. M. Gardier and B. P. Guiard (2012). Non-response to initial antidepressant therapy. Psychology. Rijeka, Croatia, InTech.<\/p>\n\n\n\n<p>&nbsp;Deltheil, T., B. Guiard, J. P. Guilloux, D. David, F. Coudore and A. M. Gardier (2012). S\u00e9rotonine et facteurs neurotrophiques dans la d\u00e9pression. S\u00e9rotonine: aspects biologiques et cliniques. O. Spreux-Varoquaux. Paris, Lavoisier &#8211; M\u00e9decine Sciences. 1: 329-370.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Assistant Professor PhD, HDR Tel: &nbsp;+33(0)1.80.00.63.35 Area of Research Neuropharmacology, Neurobiology of Depression\/Anxiety, Animal Models of Psychiatric Disorders, Genetics. Expertise Expression profiles of genes in limbic areas in animal models of depression: links with human pathology? Gene Networks involved in mood disorders. Research Theme I graduated in 2003 and obtained fundings to do pursue with&hellip; <br \/> <a class=\"read-more\" href=\"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/?page_id=157\">Lire la suite<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/157"}],"collection":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=157"}],"version-history":[{"count":11,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/157\/revisions"}],"predecessor-version":[{"id":626,"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=\/wp\/v2\/pages\/157\/revisions\/626"}],"wp:attachment":[{"href":"http:\/\/www.neuropharmacologie.universite-paris-saclay.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}